Group 1 - The core point of the article indicates that Meihao Medical (301363) experienced a stock price decline of 8.76% to 30.1 yuan as of February 26, 2026, with a trading volume of 225,800 hands and a total transaction amount of 691 million yuan [1] - On February 26, the net outflow of main funds was 84.23 million yuan, accounting for 12.18% of the total transaction amount, while retail investors saw a net inflow of 79.38 million yuan, representing 11.48% of the total transaction amount [1] - The financing data shows that on the same day, the financing buy amounted to 60.81 million yuan, while financing repayment was 71.34 million yuan, resulting in a net repayment of 10.53 million yuan [2] Group 2 - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, but a net profit attributable to shareholders of 208 million yuan, which is a year-on-year decrease of 19.25% [3] - The third quarter of 2025 saw a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit attributable to shareholders of 93.90 million yuan, reflecting a year-on-year increase of 5.89% [3] - The company has a debt ratio of 11.43% and a gross profit margin of 39.34%, indicating a stable financial position within the industry [3]
美好医疗（301363）2月26日主力资金净卖出8423.10万元